|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Kite, a Gilead Company, Continues to Advance Research With Longest CAR T Cell Therapy Follow-up Data at the 4th European CAR T-cell Meeting |
 |
|
• Pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphoma
• Safety management data in relapsed/refractory diffuse large B cell lymphoma
“We are pleased to support the 4th European CAR T-cell Meeting with presentations demonstrating potential long-term survival with CAR T cell therapy in relapsed/refractory diffuse large B cell lymphoma,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “First European presentations of our pivotal head-to-head ZUMA-7 trial and patient-reported outcomes in second-line relapsed/refractory diffuse large B cell lymphoma also support our ongoing commitment to patients with hard-to-treat blood cancers.”
ZUMA-1: Axicabtagene Ciloleucel
Updated overall survival results at five years from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (Yescarta®) in patients with relapsed/refractory diffuse large B cell lymphoma will be presented.
ZUMA-7: Axicabtagene Ciloleucel
The first European presentation of the pivotal Phase 3 ZUMA-7 study primary analysis and patientreported outcomes, evaluating the safety and efficacy of axicabtagene ciloleucel versus current standard of care for second-line therapy in relapsed/refractory diffuse large B cell lymphoma.
Study Name and Abstract Number
|
Abstract Title
Primary Author
|
ZUMA-1 Cohort 6 One-Year
Poster Number: AS-CART-2022-00058
PT02-4 Thurs 10 Feb, 19:29 CET |
Prophylactic Corticosteroids with Axicabtagene Ciloleucel (Axi-Cel) in Patients with
Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Olalekan O. Oluwole |
ZUMA-7 Elderly Poster Number: AS-CART-2022-00054 PT02-1
Thurs 10 Feb, 19:20 CET |
Superiority of Axicabtagene Ciloleucel (Axi-Cel) in SecondLine (2L) Large B-Cell Lymphoma (LBCL) in the Elderly Tom van Meerten |
ZUMA-1 Five-Year Overall Survival Poster Number: AS-CART-2022-00058
|
Long-Term (5 Year) Overall Survival in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) Caron A. Jacobson
|
Real World Evidence: CIBMTR Registry Asian Descent Subset Analysis Poster Number:
AS-CART-2022-00138
|
Real-world Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-cell Lymphoma (LBCL): Subset Analysis of Patients with Asian Descent Tanya Siddiqi |
ZUMA-7 Primary Analysis Poster Number: AS-CART-2022-00055
|
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma Frederick L. Locke |
| Health Economics and Outcomes
Research: ZUMA-7 Patient
Reported Outcomes
Poster Number:
AS-CART-2022-00057 |
Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma Mahmoud Elsawy |
| ZUMA-5 Two-Year Follow-Up Poster Number: AS-CART-2022-00053 |
Long-Term Follow-Up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) Julio Chavez |
ZUMA-12 Primary Analysis Poster Number: AS-CART-2022-00049
|
Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) Julio Chavez/Sattva S. Neelapu |
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
X‑Chem and Excelra’s GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets
LONDON and HYDERABAD, India; Feb. 9, 2022 – A new collaboration
between data science and analytics leader, Excelra, and artificial
intelligence pioneer X-Chem will accelerate preclinical drug discovery
and aid scientists to find new drug candidates for currently
hard-to-drug targets.
More info >> |
|
 |
White Papers |
 |
|
Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling
Sartorius Group
The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >> |
|
|
